Summary
The goal of this SBIR Research Topic is to support small businesses in the development of new drug classes with novel mechanisms of action for HIV, Hepatitis B (HBV), and Tuberculosis (Mtb). HBV and Mtb drugs must be compatible with current antiretroviral therapy regimens. The goal of this contract is to build a prototype mRNA vaccine containing Mtb-antigens as a safe and effective multivalent therapeutic vaccine against tuberculosis.
